Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
. 2010 Jun:77 Suppl 1:S3-100.
doi: 10.1016/S1297-319X(10)70001-4. Epub 2010 Jun 17.

Tocilizumab: therapy and safety management

Thao Pham  1 , Pascal Claudepierre, Arnaud Constantin, Michel de Bandt, Bruno Fautrel, Laure Gossec, Jacques-Eric Gottenberg, Philippe Goupille, Séverine Guillaume, Eric Hachulla, Charles Masson, Jacques Morel, Xavier Puéchal, Alain Saraux, Thierry Schaeverbeke, Daniel Wendling, Eric Bruckert, Stanislas Pol, Xavier Mariette, Jean Sibilia; Club Rhumatismes et Inflammation (CRI)
Affiliations

Tocilizumab: therapy and safety management

Thao Pham et al. Joint Bone Spine. 2010 Jun.

Abstract

Objectives: To develop fact sheets about tocilizumab, in order to assist physicians in the management of patients with inflammatory joint disease.

Methods: 1. selection by a committee of rheumatology experts of the main topics of interest for which fact sheets were desirable; 2. identification and review of publications relevant to each topic; 3. development of fact sheets based on three levels of evidence: evidence-based medicine, official recommendations, and expert opinion. The 20 experts were rheumatologists and invited specialists in other fields, and they had extensive experience with the management of RA. They were members of the CRI (Club Rhumatismes et Inflammation), a section of the Société Francaise de Rhumatologie. Each fact sheet was revised by several. experts and the overall process was coordinated by three experts.

Results: Several topics of major interest were selected: contraindications of tocilizumab; the management of adverse effects and concomitant diseases that may develop during tocilizumab therapy; and the management of everyday situations such as pregnancy, surgery, and immunizations. After a review of the literature and discussions among experts, a consensus was developed about the content of the fact sheets presented here. These fact sheets focus on several points: Several topics of major interest were selected: contraindications of tocilizumab; the management of adverse effects and concomitant diseases that may develop during tocilizumab therapy; and the management of everyday situations such as pregnancy, surgery, and immunizations. After a review of the literature and discussions among experts, a consensus was developed about the content of the fact sheets presented here. These fact sheets focus on several points: 1. in RA, initiation and monitoring of tocilizumab therapy, management of patients with specific past histories, and specific clinical situations such as pregnancy; 2. diseases other than RA, such as juvenile idiopathic arthritis; 3. models of letters for informing the rheumatologist and general practitioner; 4. and patient information.

Conclusion: These tocilizumab fact sheets built on evidence-based medicine and expert opinion will serve as a practical tool for assisting physicians who manage patients on tocilizumab therapy. They will be available continuously at www.cri-net.com and updated at appropriate intervals.

PubMed Disclaimer

Similar articles

  • Abatacept therapy and safety management.
    Pham T, Bachelez H, Berthelot JM, Blacher J, Claudepierre P, Constantin A, Fautrel B, Gaujoux-Viala C, Goëb V, Gossec L, Goupille P, Guillaume-Czitrom S, Hachulla E, Lequerré T, Marolleau JP, Martinez V, Masson C, Mouthon L, Puéchal X, Richette P, Saraux A, Schaeverbeke T, Soubrier M, Viguier M, Vittecoq O, Wendling D, Mariette X, Sibilia J. Pham T, et al. Joint Bone Spine. 2012 Mar;79 Suppl 1:3-84. doi: 10.1016/S1297-319X(12)70011-8. Joint Bone Spine. 2012. PMID: 22541956
  • TNF alpha antagonist therapy and safety monitoring.
    Pham T, Bachelez H, Berthelot JM, Blacher J, Bouhnik Y, Claudepierre P, Constantin A, Fautrel B, Gaudin P, Goëb V, Gossec L, Goupille P, Guillaume-Czitrom S, Hachulla E, Huet I, Jullien D, Launay O, Lemann M, Maillefert JF, Marolleau JP, Martinez V, Masson C, Morel J, Mouthon L, Pol S, Puéchal X, Richette P, Saraux A, Schaeverbeke T, Soubrier M, Sudre A, Tran TA, Viguier M, Vittecoq O, Wendling D, Mariette X, Sibilia J. Pham T, et al. Joint Bone Spine. 2011 May;78 Suppl 1:15-185. doi: 10.1016/S1297-319X(11)70001-X. Joint Bone Spine. 2011. PMID: 21703545
  • Tocilizumab for rheumatoid arthritis.
    Singh JA, Beg S, Lopez-Olivo MA. Singh JA, et al. Cochrane Database Syst Rev. 2010 Jul 7;(7):CD008331. doi: 10.1002/14651858.CD008331.pub2. Cochrane Database Syst Rev. 2010. PMID: 20614469 Review.
  • Use of glucocorticoids in rheumatoid arthritis - pratical modalities of glucocorticoid therapy: recommendations for clinical practice based on data from the literature and expert opinion.
    Dernis E, Ruyssen-Witrand A, Mouterde G, Maillefert JF, Tebib J, Cantagrel A, Claudepierre P, Fautrel B, Gaudin P, Pham T, Schaeverbeke T, Wendling D, Saraux A, Loët XL. Dernis E, et al. Joint Bone Spine. 2010 Oct;77(5):451-7. doi: 10.1016/j.jbspin.2009.12.010. Epub 2010 May 14. Joint Bone Spine. 2010. PMID: 20471886 Review.
  • Abatacept therapy and safety management.
    Pham T, Claudepierre P, Constantin A, Fautrel B, Gossec L, Gottenberg JE, Goupille P, Hachulla E, Masson C, Morel J, Saraux A, Schaeverbeke T, Wendling D, Mariette X, Sibilia J. Pham T, et al. Joint Bone Spine. 2009 May;76 Suppl 1:S3-S55. doi: 10.1016/S1297-319X(09)74520-8. Joint Bone Spine. 2009. PMID: 19560051 Review.
See all similar articles

Cited by

See all "Cited by" articles

Publication types

LinkOut - more resources

-